December 21, 2017 / 12:11 PM / 9 months ago

BRIEF-Biogen Inc - Results Of Final Analysis On BAN2401 Are Expected During Second Half Of 2018

Dec 21 (Reuters) - Biogen Inc:

* ADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER’S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT

* BIOGEN INC - RESULTS OF FINAL ANALYSIS ON BAN2401 ARE EXPECTED TO BE OBTAINED DURING SECOND HALF OF 2018

* BIOGEN- INDEPENDENT DATA MONITORING COMMITTEE SAID BAN2401 DID NOT MEET SUCCESS CRITERIA BASED ON BAYESIAN ANALYSIS AT 12 MONTHS AS PRIMARY ENDPOINT IN STUDY 201

* BIOGEN INC - BLINDED STUDY WILL CONTINUE AND COMPREHENSIVE FINAL ANALYSIS WILL BE CONDUCTED AT 18 MONTHS TO DEMONSTRATE CLINICALLY SIGNIFICANT RESULTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below